See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report for: STXS
ST. LOUIS, May 04, 2016 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco. During its 12th consecutive appearance at HRS, the Company will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at Booth #1631.
“We are excited to bring together expert users of our remote magnetic navigation platform and physicians searching for treatment options that provide improved outcomes for complex cardiac arrhythmias with a lower risk of adverse events and reduced fluoro exposure to patients and physicians,” said William C. Mills, Stereotaxis Chief Executive Officer. “Inspired by an abundance of clinical data and empirical evidence, hospitals and physicians worldwide are turning to our magnetic navigation and automation solutions to strengthen their leadership in cardiac rhythm management by simplifying and significantly enhancing therapy delivery, especially in the complex clinical setting of ventricular arrhythmias.”
In the HRS Rhythm Theatre on Friday, May 6, Stereotaxis will host a lunch symposium featuring the latest insights and clinical research by experienced users. Chaired by Dr. Mauricio Arruda (University Hospitals Case Medical Center), who has completed more than 1,200 procedures using the Niobe® remote magnetic navigation system, the session will provide impressive clinical results of the Niobe system in the treatment of ischemic and non-ischemic ventricular tachycardia (VT) patients, and a discussion of the Company’s multi-center, randomized, superiority study of VT ablation outcomes. Guest speakers include Dr. Luigi Di Biase (Albert Einstein College of Medicine at Montefiore Hospital), Dr. Hiroshi Nakagawa (Oklahoma University Medical Center), and Dr. Tamas Szili-Torok (Erasmus Medical Center).
Dr. Andrea Natale, Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, recently spoke to EP Lab Digest about the value and potential of remote magnetic navigation in electrophysiology for its May issue, which will be available at HRS. In the article, Dr. Natale said, “The people that have actually invested the time to become proficient with remote magnetic navigation and its learning curve, and addressed the differences between magnetic and manual navigation, love this technology and find it difficult when magnetic navigation cannot be used in a procedure.” Dr. Natale is serving as global principal investigator for the Company’s MAGNETIC-VT multi-center randomized study, which he believes could establish remote magnetic navigation as the “gold standard” for certain VT procedures.
In its exhibit space, Stereotaxis will highlight the latest innovations to its Niobe system including the next generation user interface, which includes new features such as improved catheter tip-to-tissue contact confirmation based on bipolar impedance information. During the HRS Rhythm Theatre on Friday, May 6, Dr. Hiroshi Nakagawa will also share the development progress for the lesion assessment and prediction tool called Magnetic Ablation Index. Each of these software features can provide valuable information to physicians while they are ablating tissue and also furthers the ongoing efforts to fully automate the execution of physician-defined ablation strategies. Finally, the Company will unveil its newly developed, software-based simulation platform for physician training, alongside a modeled beating heart phantom that demonstrates the mechanics of its technologies in effective lesion creation – paramount to acute and long-term success – within the most difficult to reach and navigate regions of the heart.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
Source – Company Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news